<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">34334</article-id><article-id pub-id-type="doi">10.7554/eLife.34334</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Serine is the major residue for ADP-ribosylation upon DNA damage</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-88463"><name><surname>Palazzo</surname><given-names>Luca</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5556-5549</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-102977"><name><surname>Leidecker</surname><given-names>Orsolya</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-102978"><name><surname>Prokhorova</surname><given-names>Evgeniia</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5467-5586</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107379"><name><surname>Dauben</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-88465"><name><surname>Matic</surname><given-names>Ivan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0170-7991</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-34890"><name><surname>Ahel</surname><given-names>Ivan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9446-3756</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Sir William Dunn School of Pathology</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution>Max Planck Institute for Biology of Ageing</institution>, <addr-line><named-content content-type="city">Cologne</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1078"><name><surname>Dikic</surname><given-names>Ivan</given-names></name><role>Reviewing editor</role><aff><institution>Goethe University Frankfurt</institution>, <country>Germany</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>imatic@age.mpg.de</email> (IM);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>ivan.ahel@path.ox.ac.uk</email> (IA);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>02</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e34334</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>02</month><year>2018</year></date></history><permissions><copyright-statement>Â© 2018, Palazzo et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Palazzo et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-34334-v1.pdf"/><abstract><p>PARPs are a family of enzymes that synthesise ADP-ribosylation (ADPr), a reversible modification of proteins that regulates many different cellular processes. Several mammalian PARPs are known to regulate the DNA damage response, but it is not clear which amino acids in proteins are the primary ADPr targets. Previously we reported that ARH3 reverses the newly discovered type of ADPr (ADPr on serine residues; Ser-ADPr) and developed tools to analyse this modification  (Fontana et al, 2017). Here we show that Ser-ADPr represents the major fraction of ADPr synthesised after DNA damage in mammalian cells and that globally Ser-ADPr is dependent on HPF1, PARP1 and ARH3. In the absence of HPF1, glutamate/aspartate become the main target residues for ADPr. Furthermore, we describe a method for site-specific validation of serine ADP-ribosylated substrates in cells. Our study establishes serine as the primary form of ADPr in DNA damage signalling.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>101794</award-id><principal-award-recipient><name><surname>Ahel</surname><given-names>Ivan</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C35050/A22284</award-id><principal-award-recipient><name><surname>Ahel</surname><given-names>Ivan</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010661</institution-id><institution>Horizon 2020 Framework Programme</institution></institution-wrap></funding-source><award-id>657501</award-id><principal-award-recipient><name><surname>Matic</surname><given-names>Ivan</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>EXC 229</award-id><principal-award-recipient><name><surname>Matic</surname><given-names>Ivan</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010661</institution-id><institution>Horizon 2020 Framework Programme</institution></institution-wrap></funding-source><award-id>281739</award-id><principal-award-recipient><name><surname>Ahel</surname><given-names>Ivan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec sec-type="supplementary-material"><supplementary-material><ext-link xlink:href="elife-34334-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>